Switch to
More onapp

Lasa Supergenerics Ltd

LASA
Health CarePharmaceuticals
SmallcapWith a market cap of ₹133 cr, stock is ranked 2,035
High RiskStock is 3.86x as volatile as Nifty
32.200.65 (-1.98%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹133 cr, stock is ranked 2,035
High RiskStock is 3.86x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
-24.93
PB RatioPB Ratio
0.90
Dividend YieldDiv. Yield
0.76%
Sector PESector PE
35.92
Sector PBSector PB
4.36
Sector Div YldSctr Div Yld
0.88%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Lasa Supergenerics Limited is an India-based veterinary active pharmaceutical ingredients (API) manufacturing company. The Company is engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, pharmaceuticals, drugs and others. It specializes in catalyst chemistry and manufactures anthelmintic/veterinary API products. The Company's products include API products, other API products, animal feed ingredients and reagents for therapeutic use. Its API products include Albendazole, Fenbendazole, Oxfendazole, Providone Iodine, Nitroxylene, Ricobendazole, Halquinol and others. Its animal feed ingredients include potassium iodide, cobalt sulfate, sodium selenate, ethylediamine dihydroiodide and vanadyl sulfate. Its reagents for therapeutic use include cetylpyridinium chloride, bismuth subsalicylate and sodium selenite. The Company's manufacturing facility is located at Mahad and Chiplun, Maharashtra.

Financial TrendFinancial statements 

2019202020212022170.04167.49202.44137.19-12.043.6222.78-5.36
Revenue
Profit
Loss
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Outcome of Board Meeting 
Announced OnNov 14, 2022

Lasa Supergenerics Limited has informed the Exchange about Board Meeting held on 14-Nov-2022 to consider unaudited financial statements for the period ended September 2022 | Download

Lasa Supergenerics Limited has informed the Exchange about Board Meeting held on 14-Nov-2022 to consider unaudited financial statements for the period ended September 2022 | Download

General updates 
Announced OnOct 18, 2022

Lasa Supergenerics Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 | Download

Lasa Supergenerics Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 | Download

Cash Dividend 
Ex. DateSep 16, 2022

Final • Div/Share: ₹ 0.25

See all events